| 1 |
Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience |
|
| | Vivekanandan Kalaiselvan, Shatrunajay Shukla, Shubhang Arora, Tarani Prakash Shrivastava, Rajeev Singh Raghuvanshi | | | Frontiers in Public Health. 2022; 10 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Revue de la littérature sur la pharmacovigilance des médicaments issus des pharmacopées traditionnelles. Partie II : évaluation et prévention des risques |
|
| | K. Ouoba, H. Lehmann, J.-Y. Pabst, R. Semde | | | Annales Pharmaceutiques Françaises. 2021; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme |
|
| | Josiah Tatenda Masuka, Star Khoza | | | Pharmacology Research & Perspectives. 2020; 8(5) | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
System of adverse drug reactions reporting: What, where, how, and whom to report? |
|
| | Vivekanandan Kalaiselvan, Pranay Kumar, Prabhakar Mishra, Gyanendra Singh | | | Indian Journal of Critical Care Medicine. 2015; 19(9): 564 | | | [Pubmed] [Google Scholar] [DOI] | |
|
